Regenerative medical technology company LYMA published its financial results for fiscal year 2025, reporting revenues of $48 million. The company attributes its significant growth to its successful expansion into the United States market.
“2025 was a transformative year for LYMA as we solidified our position in the US market and demonstrated the global appetite for truly innovative regenerative technology,” said Lucy Goff, founder and chief executive officer. “Our success reflects our unwavering commitment to delivering clinically-proven results through cutting-edge science, and we’re seeing that resonate particularly strongly with American consumers who demand both efficacy and luxury.”
LYMA launched its LYMA PRO laser in the United States in April 2025. The laser is powered by a 1450mW near-infrared continuous cold laser beam at 808nm. According to the company’s press release, the device penetrates up to 10cm into the dermis where it lifts skin and muscle simultaneously.
Following the launch in April, DTC sales in the first six months were up to 130%. LYMA PRO was endorsed and supported by beauty and science industry experts, including Bobbi Brown, Miranda Kerr, Dr. Jason Diamond and Dr. Dan Belkin.
The company hopes to continue its expansion in 2026 in both the United States and the United Kingdom, with plans to deepen its presence in these key markets. Further, LYMA also plans to establish its presence in other key regions, such as Australia and the United Aram Emirates.
“We are super excited to continue our expansion in the US and other key markets at the same time as bringing new products to market later in 2026,” Goff concluded.
